Business Wire

Patient Safety Movement Foundation Welcomes New Leadership

21.10.2021 15:00:00 EEST | Business Wire | Press release

Share

The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, today announced Michael A.E. Ramsay, MD, FRCA as its new chief executive officer. Following his appointment, Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc will assume Ramsay’s previous role as chairman. Under their leadership, the organization looks forward to continuing to improve patient safety around the globe.

Dr. Ramsay assumes the role from former CEO, David B. Mayer, MD, who played a pivotal part in helping the organization launch the inaugural #UniteForSafeCare event. During his tenure, Mayer also introduced a new commitment model making it easier for hospitals and healthcare organizations to prioritize patient safety and was a driving force behind the call for a Patient Safety Moonshot.

“We are grateful for all of Dr. Mayer’s efforts over the past three years and believe that Dr. Ramsay is the right leader for this next chapter,” stated Ariana Longley, MPH, chief operating officer at the Patient Safety Movement Foundation. “The leadership, expertise, passion and global connections that Dr. Ramsay and Dr. Durkin bring to the organization position us well to achieve our audacious goals.”

“I am honored to be appointed as CEO,” said Dr. Ramsay. “The last year and a half has put a spotlight on the gaps in our healthcare system. I am excited to work in lockstep with the strong leadership and team at PSMF to forge partnerships that actively promote change, develop and disseminate patient safety education material and create public demand for safe and highly reliable healthcare.”

Prior to being named CEO, Dr. Ramsay was an early member of PSMF set up by Joe Kiani in 2012 and most recently served as chairman of PSMF since 2020. He brings extensive experience serving as chairman emeritus of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas. He is also a professor at the Texas A&M Health Science Center and holds a clinical professorship in anesthesiology at the University of Texas Southwestern Medical School. Ramsay was president of the Baylor Scott and White Research Institute from 2000 to 2020, where the focus was on developing cancer vaccines and early cancer biomarkers. He is past director of anesthesia for the liver transplant program at Baylor and has personally provided anesthesia for over 1,000 liver transplant recipients. He has also held roles in numerous groups, including a current member of the Baylor University Medical Center board of trustees, past president of the International Liver Transplantation Society, committee member of the United Network for Organ Sharing and a member of the American Society of Anesthesiologists committee on transplant anesthesia and “Failure to Rescue: Post-operative Respiratory Depression” workgroup of the PSMF. He was born in Dublin, Ireland, went to Brentwood School in the UK and trained in medicine at The Royal London Hospital. Ramsay was recruited by Baylor University Medical Center in Dallas, Texas in 1976.

Dr. Durkin has been a member of PSMF since 2012 and is transitioning from vice chairman to chairman. Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. Passionate about patient safety, he played an integral role in the assembly of the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. Durkin was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019). Outside of PSMF, he has served as the national director of patient safety for England’s NHS, executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities.

“I am honored to continue to work with the Patient Safety Movement Foundation in this role,” states Durkin. “We have made great progress but are now at a time when we must issue a call to urgent and sustained action for all patients and families as well as political and healthcare leaders, nurses, doctors, pharmacists and therapists of every dimension to continue to educate and empower others to help us reach our goal of zero.”

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye